Condition at Center of NFL Lawsuit Targeted by Medical Marijuana Company
A plant-based pharmaceutical company is working on developing a medical marijuana treatment for chronic traumatic encephalopathy (CTE), a degenerative disease that affects people—particularly athletes—who have suffered repeated head trauma.
We’re really looking at the athlete brain,” Thoma Kikis, the company’s chief visionary officer, told FoxNews.com. Their goal is to create a treatment that is both preventative and therapeutic for those already diagnosed with CTE.
Dean Petkanas, the chief executive of KannaLife Sciences, expects the federal government to pave the way for medical marijuana within two years, he told Varney & Co. on Monday.
